We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+19.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.84B
AUM Growth
+$680M
Cap. Flow
+$205M
Cap. Flow %
7.2%
Top 10 Hldgs %
32.58%
Holding
110
New
34
Increased
20
Reduced
17
Closed
25

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$55M
2
LLY icon
Eli Lilly
LLY
+$52.4M
3
MCK icon
McKesson
MCK
+$51.5M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$41.6M
5
ABBV icon
AbbVie
ABBV
+$40.8M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$114M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.6M
3
XYZ
Block Inc
XYZ
+$29.5M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$20.8M
5
MSFT icon
Microsoft
MSFT
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 79.08%
2 Financials 0.38%
3 Consumer Discretionary 0%
4 Industrials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
51
Cytokinetics
CYTK
$10.4B
$20.2M 0.71%
+971,151
New +$17.7M
CNC icon
52
Centene
CNC
$32.5B
$19.7M 0.69%
+328,479
New +$20.9M
NVAX icon
53
CALL
Novavax
NVAX
$1.31B
$16.7M 0.59%
+150,000
New +$15.9M
STTK icon
54
Shattuck Labs
STTK
$694M
$16.2M 0.57%
+386,813
New +$12.4M
LONA
55
LeonaBio Inc
LONA
$72.1M
$16.1M 0.57%
47,023
+7,774
+20% +$1.83M
HZNP
56
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$15.9M 0.56%
+217,900
New +$16.2M
IONS icon
57
Ionis Pharmaceuticals
IONS
$9.4B
$14.9M 0.52%
+263,412
New +$13.1M
ADAP
58
DELISTED
Adaptimmune Therapeutics
ADAP
$14.5M 0.51%
2,694,769
+1,845,329
+217% +$10M
ZLAB icon
59
Zai Lab
ZLAB
$2.62B
$14.5M 0.51%
+107,061
New +$10.9M
ACAD icon
60
CALL
Acadia Pharmaceuticals
ACAD
$5.03B
$14.4M 0.51%
+270,000
New +$13.4M
KNTE
61
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$13.6M 0.48%
+341,905
New +$13.7M
CNST
62
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$13.5M 0.48%
469,664
-825,313
-64% -$20.8M
DVAX
63
DELISTED
Dynavax Technologies
DVAX
$13.1M 0.46%
2,936,990
– –
SPRB
64
Spruce Biosciences
SPRB
$129M
$12.9M 0.45%
+7,057
New +$11.7M
MYOV
65
CALL
DELISTED
Myovant Sciences Ltd.
MYOV
$11.4M 0.4%
+411,500
New +$8.01M
MRTX
66
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.73M 0.34%
44,300
-112,800
-72% -$24.4M
TRIL
67
DELISTED
Trillium Therapeutics Inc.
TRIL
$8.81M 0.31%
599,111
-527,214
-47% -$7.6M
SPRY icon
68
ARS Pharmaceuticals
SPRY
$612M
$8.72M 0.31%
+188,243
New +$6.29M
PACB icon
69
PUT
Pacific Biosciences
PACB
$370M
$8.3M 0.29%
+320,000
New +$5.44M
RVMD icon
70
Revolution Medicines
RVMD
$44B
$8.28M 0.29%
209,116
-151,197
-42% -$5.98M
CERT icon
71
Certara
CERT
$1.25B
$7.69M 0.27%
+228,000
New +$8.35M
LAB icon
72
Standard BioTools
LAB
$314M
$6.34M 0.22%
1,056,343
– –
CRSP icon
73
PUT
CRISPR Therapeutics
CRSP
$5.17B
$6.28M 0.22%
+41,000
New +$4.85M
RCUS icon
74
CALL
Arcus Biosciences
RCUS
$3.64B
$6.16M 0.22%
237,300
-2,700
-1% -$65.4K
BLSA
75
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.51M 0.19%
+500,000
New +$5.36M
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q4 2020 Portfolio in Review

As of Q4 2020, PFM Health Sciences held 110 positions worth $2.84B, up 31% from $2.16B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

PFM Health Sciences deployed $205M of net new capital in Q4 2020, opening 34 new positions and adding to 20 existing holdings. Its largest new stake was Universal Health Services: 442,044 shares worth $60.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 68% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $30.6M trimmed.

  • PFM Health Sciences's largest Q4 2020 buy was Universal Health Services: 442,044 shares worth $60.8M.
  • PFM Health Sciences added most to Acadia Pharmaceuticals in Q4 2020, an estimated $41.6M increase.
  • PFM Health Sciences's biggest Q4 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $30.6M.
  • PFM Health Sciences fully exited Immunomedics Inc in Q4 2020, selling an estimated $114M.
  • PFM Health Sciences's ten largest holdings make up 33% of its $2.84B portfolio in Q4 2020.
  • PFM Health Sciences opened 34 new positions and closed 25 in Q4 2020.
  • PFM Health Sciences's portfolio value rose 31% quarter-over-quarter to $2.84B.

Based on PFM Health Sciences's 13F filing for Q4 2020, filed 16 Feb 2021.